| 11/16/2026 5:18 PM | Silence Therapeutics (1479615) Subject TCG Crossover GP I, LLC (1839947) Filed by | Form SCHEDULE 13G/A | |
| 11/12/2026 11:51 AM | Invus Global Management, LLC (2005369) Filed by Silence Therapeutics (1479615) Subject | Form SCHEDULE 13G/A | |
| 11/12/2026 7:15 AM | Silence Therapeutics (1479615) Filer | Form DEFA14A | |
| 11/12/2026 7:10 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/05/2026 12:24 PM | FMR LLC (315066) Filed by Silence Therapeutics (1479615) Subject | Form SCHEDULE 13G | |
| 10/19/2026 3:10 PM | Silence Therapeutics (1479615) Filer | Form DEFA14A | |
| 10/19/2026 7:13 AM | Silence Therapeutics (1479615) Filer | Form DEFA14A | |
| 10/19/2026 7:05 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/13/2026 6:15 PM | Silence Therapeutics (1479615) Subject Tetragon Financial Management LP (1758892) Filed by | Form SCHEDULE 13G/A | |
| 10/13/2026 3:05 PM | Silence Therapeutics (1479615) Subject Tetragon Financial Management LP (1758892) Filed by | Form SCHEDULE 13G | |
| 08/13/2026 8:55 PM | Griffiths Richard Ian (1846370) Filed by Silence Therapeutics (1479615) Subject | Form SCHEDULE 13D/A | |
Get the Latest News and Ratings for SLNCF and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/13/2026 10:13 AM | Invus Global Management, LLC (2005369) Filed by Silence Therapeutics (1479615) Subject | Form SCHEDULE 13G/A | |
| 08/13/2026 9:07 AM | Griffiths Richard Ian (1846370) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/12/2026 4:23 PM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/12/2026 4:21 PM | Silence Therapeutics (1479615) Filer | Form 424B5 | |
| 08/11/2026 8:59 PM | Silence Therapeutics (1479615) Filer | Form S-3MEF | |
| 08/10/2026 4:03 PM | Silence Therapeutics (1479615) Filer | Form 424B5 | |
| 08/10/2026 6:57 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/10/2026 6:26 AM | Silence Therapeutics (1479615) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/10/2026 6:20 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/16/2026 4:20 PM | Silence Therapeutics (1479615) Filer | Form 8-K/A | |
| 07/08/2026 6:00 AM | Griffiths Richard Ian (1846370) Filed by Silence Therapeutics (1479615) Subject | Form SCHEDULE 13D/A | |
| 07/07/2026 8:09 AM | Griffiths Richard Ian (1846370) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 3:35 PM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/16/2026 4:00 PM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/11/2026 6:35 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/27/2026 11:15 PM | Silence Therapeutics (1479615) Filer | Form EFFECT | |
| 05/27/2026 3:53 PM | Silence Therapeutics (1479615) Filer | Form 424B5 | |
| 05/18/2026 4:00 PM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/07/2026 7:22 AM | Silence Therapeutics (1479615) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/07/2026 7:15 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/05/2026 6:40 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/05/2026 6:49 AM | Silence Therapeutics (1479615) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/13/2026 5:02 AM | Griffiths Richard Ian (1846370) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/09/2026 12:16 PM | Lombard Odier Asset Management (0) USA Silence Therapeutics (1479615) Subject | Form SCHEDULE 13G/A | |
| 01/06/2026 3:15 PM | Lemus David (1717972) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:15 PM | HELLUMS RHONDA LYNETTE (1766456) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:15 PM | Romano Steven J. (1639860) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:15 PM | MCINERNEY TIMOTHY (1226020) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:15 PM | Ede-Golightly James (2048873) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/22/2025 5:02 PM | Ede-Golightly James (2048873) Reporting Silence Therapeutics (1479615) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
The next convergence is here (Ad) In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months.
This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time.
Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it. See the three companies positioned for uranium's next supply shock |
| 12/22/2025 5:03 PM | Ede-Golightly James (2048873) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/22/2025 5:04 PM | Ross Iain (1307218) Reporting Silence Therapeutics (1479615) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/22/2025 3:01 PM | Silence Therapeutics (1479615) Filer | Form 8-K/A | |
| 12/22/2025 6:32 AM | Silence Therapeutics (1479615) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |